Nihal Sinha

Board Director at Ensoma

London, England

Overview

Nihal Sinha is a Partner at F-Prime Capital in London, specializing in venture capital investments in the healthcare and life sciences sectors. With a background in clinical research and management consulting, he has successfully invested in companies like T-Therapeutics and Elucidata, demonstrating a strong track record in supporting start-ups through various stages of growth.

Work Experience

F-Prime Capital

Partner
2014 - Current
F-Prime Capital is a global venture capital firm investing in healthcare and technology companies.

F-Prime Capital is a venture capital firm investing in healthcare and technology.

fprimecapital.com

T-Therapeutics Ltd

Board Director
2023

CHARM Therapeutics

Board Director, Founding Investor
2021

Ensoma

Board Director
2023

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

Raised $205,000,000.00 from Delos Capital, Bioluminescence Ventures, Kite Pharma, SymBiosis LLC, Catalio Capital Management, Solasta Ventures, Qatar Investment Authority, Mirae Asset, 5AM Ventures and Alexandria Venture Investments.

ensoma.com